Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map
Immune Response BioPharma, Inc. TM     (c) 2010-2017 
 
Sepsicillin   TM    Sepsis Antibiotic 
 
 
 
 
undefined

 

Sepsicillin: TM IR-999 Sepsis Antibiotic BPI Formulation Phase 1 Planning

                              First in Class Sepsis Treatment

 
 
 
Bactericidal/Permeability-Increasing protein (BPI)
 
BPI is found in human white blood cells and has a broad spectrum affect on
 
gram negative bacteria when used in combinations with other antibiotics it
 
is a potential potent new drug application for the treatment of Sepsis.
 
Sepsis or Septicemia is an infection of the blood caused by microbes and bacteria resulting in blood poison. Bacterial infections begin when bacteria or other infectious agents enter enter the body. Sepsis Shock occurs when the infection leads to a life threathening drop in blood pressure. This may lead to the loss of vital organs and cause death.
 
 
 
 
 
 
Immune Response BioPharma, Inc. TM

Copyright © 2010-2017